Anaphylactic shock associated with intravenous amiodarone  by Serhan Özcan, Kazım et al.
CA
K
E
D
a
A
R
R
2
A
K
A
A
D
I
t
d
i
a
e
a
e
m
[
w
C
m
S
T
(
1
hJournal of Cardiology Cases 9 (2014) 61–62
Contents lists available at www.sciencedirect.com
Journal  of  Cardiology  Cases
journa l h om epage: www.elsev ier .com/ locate / j ccase
ase  Report
naphylactic  shock  associated  with  intravenous  amiodarone
azım  Serhan  Özcan  (MD) ∗, Ahmet  Zengin  (MD),  Adem  Tatlısu  (MD),
mre Arug˘arslan  (MD),  Zekeriya  Nurkalem  (MD)
epartment of Cardiology, Siyami Ersek Cardiovascular and Thoracic Surgery Center, Istanbul, Turkey
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 19 August 2013
eceived in revised form
6 September 2013
ccepted 4 October 2013
eywords:
naphylactic shock
miodarone
rug allergy
a  b  s  t  r  a  c  t
A  64-year-old  woman  was  admitted  to our emergency  department  with  shortness  of  breath  and  pal-
pitation  which  started  2 h before  her  admission.  She  had  a history  of  rheumatic  mitral  valve  disease
and  was  on  drug  treatment  with  warfarin  and  metoprolol.  The  patient  was  orthopneic,  blood  pressure
was  108/68  mmHg  with  an irregular  pulse  with  a  heart  rate  of 158  beats per  minute,  and  respiratory
rate  was  23  times  per  minute.  Her  electrocardiogram  was  consistent  with  atrial  ﬁbrillation  with rapid
ventricular  response.  For  pharmacological  cardioversion  the patient  was given  amiodarone  intravenous
loading  dose  of 300  mg in  30 min.  After  10 min  of  infusion  the  patient  complained  of  pruritus  and  skin
rash  consistent  with  urticaria.  At  the  same  time  the  patient  had  dyspnea  and  bronchoconstriction  was
noted  on both  lung ﬁelds. The  blood  pressure  was  measured  as 64/40  mmHg.  The  patient  was  taken  to
intensive  care  unit  and  supportive  treatment  for anaphylactic  shock  was given.  Amiodarone  is a class  III
antiarrhythmic  agent  frequently  used  in  the  management  of  atrial  ﬁbrillation.  This  potentially  fatal  com-
plication of  amiodarone  should  be  kept in mind  by clinicians  and  before  administration  patients  should
be  questioned  about  previous  allergic  reactions  including  previous  iodine  or iodinated  contrast  media.
Alternative  agents  should  be considered  in these  conditions.
<Learning  objective:  Anaphylactic  shock  is  a rare  complication  of  amiodarone  and  it is a commonly  used
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Amiodarone is a class III antiarrhythmic agent which is used in
reatment of supraventricular and ventricular arrhythmias. Amio-
arone has serious and potentially life-threatening side effects
ncluding pneumonitis, thyroid dysfunction, hepatitis, ophthalmic
nd neurologic disorders, and skin reactions. Because of these side
ffects, generally it is not the drug of ﬁrst choice in the treatment of
rrhythmia and long-term usage of this drug is limited due to side
ffects [1]. Allergic reactions are reported with amiodarone treat-
ent, but anaphylactic shock is a rare complication of this drug
2–5]. We hereby report a case of anaphylactic shock associated
ith intravenous amiodarone treatment.
ase reportA 64-year-old woman was admitted to our emergency depart-
ent with shortness of breath and palpitation which started 2 h
∗ Corresponding author at: Barbaros Mahallesi, Bekir Sıtkı Sezgin Sokak, Özlem
itesi, B blok, Daire: 9 Üsküdar, Kos¸ uyolu-I˙stanbul 34087, Turkey.
el.: +90 532 6742429/216 545 47 36; fax: +90 216 3379719.
E-mail addresses: serhandr@gmail.com, serhan oz@yahoo.com
K. Serhan Özcan).
878-5409/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2013.10.001plication  of amiodarone  should  be  kept  in mind  by  clinicians.>
anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
before her admission. She had a history of rheumatic mitral valve
disease and was on drug treatment with warfarin (5 mg/day) and
metoprolol (50 mg/day). She had an episode of paroxysmal atrial
ﬁbrillation 6 months previously, which returned to sinus rhythm
spontaneously and she was anticoagulated with warfarin. On  phys-
ical examination, the patient was orthopneic, blood pressure was
108/68 mmHg  with an irregular pulse with a heart rate of 158 beats
per minute, and respiratory rate was  23 times per minute. Cardiac
examination revealed diastolic murmur along the left sternal
border. Auscultation of lung ﬁelds revealed basal crepitations. Her
electrocardiogram was  consistent with atrial ﬁbrillation with rapid
ventricular response (Fig. 1). We  performed transthoracic echocar-
diography at the bedside which revealed that the patient had
rheumatic mitral and aortic valves. She had moderate mitral steno-
sis (mitral valve area measured with planimetry was 1.39 cm2) and
mild mitral and aortic regurgitation. In laboratory tests, complete
blood count, electrolytes, renal, and liver tests were normal and the
international normalized ratio was 2.6 in the therapeutic range. For
pharmacological cardioversion the patient was given amiodarone
(Cordarone 150 mg  i.v., Sanoﬁ-Aventis, Paris, France) intravenous
loading dose of 300 mg  in 30 min  (administered with 5% dextrose
solution). After 10 min  of infusion, the patient complained of
pruritus and skin rash consistent with urticaria. Perioral erythema
and edema were observed. At the same time, the patient had
dyspnea and bronchoconstriction was  noted on both lung ﬁelds.
vier Ltd. All rights reserved.
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and  nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunolig. 1. Admission electrocardiogram consistent with atrial ﬁbrillation with high
entricular response.
xygen saturation level was 90% and no signs of hypoxia were
bserved. Nasal oxygen was  administered. The blood pressure was
easured as 64/40 mmHg. The patient was taken to the intensive
are unit with a diagnosis of anaphylactic shock. The patient
as mildly confused and her Glasgow coma score was 13. The
nfusion was stopped and subcutaneous adrenaline (0.3 mg)  was
dministered and bolus isotonic saline infusion was started. The
atient was given inotropic support with dopamine (5 g/kg/min)
nd pheniramine (45.5 mg). The patient was well after 2 h and
inus rhythm was achieved spontaneously. Complete blood count
evealed elevated eosinophil count 1.2 L (0–0.7 × 103/L) and IgE
evel was elevated 740 IU/mL (7–460 IU/mL). Serum tryptase level
as 27 ng/mL (0–15 ng/mL). The patient was discharged the next
ay with a recommendation for further investigation of allergies
nd daily treatment with metoprolol (50 mg/day).
iscussion
Amiodarone is a broad-spectrum antiarrhythmic drug with
nique side effects [6]. Anaphylactic shock associated with amio-
arone is a rare condition [4,5]. It contains an iodine component
hich may  be associated with anaphylactoid reactions [6–8].
nown hypersensitivity to iodine was listed as a contraindication
o amiodarone administration, but some reports showed that pre-
ious iodine allergy was not an absolute contraindication to this
rug [6–8]. Polyoxyethylene-sorbitan-20-monooleate (also known
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as polysorbate 80 and Tween 80) is a solubilizing agent ubiqui-
tously used in medical preparations including amiodarone. In the
literature some cases have been reported regarding hypersensi-
tivity reactions due to this agent [9,10]. In our case, the patient
did not have an allergy history to any agent and this was the ﬁrst
time taking the drug. Anaphylactic shock occurred and the patient
recovered with appropriate treatment. Polyoxyethylene-sorbitan-
20-monooleate or iodine hypersensitivity may  be responsible for
anaphylactic shock in this case. It is important to realize quickly
this rare side effect of this drug and immediate treatment with
removal of the drug is crucial. Assessments of vital signs of patients
have to be done as soon as possible and advanced life support
including assisted ventilation, inotropic support, cardiopulmonary
resuscitation, antihistaminic, drugs and subcutaneous adrenaline
are essential components of treatment.
This potentially fatal complication of amiodarone should be kept
in mind by clinicians and before administration patients should
be questioned about previous allergic reactions including previ-
ous iodine or iodinated contrast media and other drug reactions.
Alternative agents should be considered in these conditions or the
infusion of the drug may  be administered in the intensive care unit
with appropriate drugs and staff.
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